NMRA - Neumora Therapeutics, Inc.

NMRA - Neumora Therapeutics, Inc.

https://www.neumoratx.com

Momentum: Bearish

Recent News

Powered by Alpha Vantage

Neumora ( NMRA ) Q2 Loss Improves 10%

Motley Fool • 1 month, 1 week ago • score: 0.16

Neumora Therapeutics ( NASDAQ:NMRA ) , a clinical-stage neuroscience company developing targeted therapies for brain diseases, released its second quarter 2025 results on August 6, 2025. The most significant news was a reduction in both research and development spending and overall net loss, ...

Neumora Therapeutics to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025

GlobeNewswire • 1 month, 3 weeks ago • score: 0.08

WATERTOWN, Mass., July 23, 2025 ( GLOBE NEWSWIRE ) -- Neumora Therapeutics, Inc. ( Nasdaq: NMRA ) , a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven brain disease programs including three clinical-stage programs, today announced that it will host a ...

Neumora Therapeutics to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025 - Neumora Therapeutics ( NASDAQ:NMRA )

Benzinga • 1 month, 3 weeks ago • score: 0.07

WATERTOWN, Mass., July 23, 2025 ( GLOBE NEWSWIRE ) -- Neumora Therapeutics, Inc. NMRA, a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven brain disease programs including three clinical-stage programs, today announced that it will host a conference call ...

Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study of M4 Positive Allosteric Modulator NMRA-861

GlobeNewswire • 2 months ago • score: 0.16

NMRA-861 has potential best-in-class pharmacology, which may enable a more favorable therapeutic profile ...

Kuehn Law Encourages Investors of Neumora Therapeutics, Inc. to Contact Law Firm - Neumora Therapeutics ( NASDAQ:NMRA )

Benzinga • 3 months, 2 weeks ago • score: 0.01

NEW YORK, May 27, 2025 ( GLOBE NEWSWIRE ) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Neumora Therapeutics, Inc. NMRA breached their fiduciary duties to shareholders.

Neumora Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025 - Neumora Therapeutics ( NASDAQ:NMRA )

Benzinga • 4 months, 2 weeks ago • score: 0.07

WATERTOWN, Mass., April 28, 2025 ( GLOBE NEWSWIRE ) -- Neumora Therapeutics, Inc. NMRA, a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven brain disease programs including two clinical-stage programs, today announced that it will host a conference call and ...

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company is headquartered in Watertown, Massachusetts.

52W High

$17.19

52W Low

$0.61

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

N/A

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

-4.65

EV/Revenue (<3 favorable)

N/A

P/S (TTM) (<3 favorable)

N/A

P/B (<3 favorable)

1.49

Ownership

Balanced

Source: Overview

Insiders (1–5% typical)

27.54%

Institutions (25–75% balanced)

54.72%

Shares Outstanding

161,945,000

Float

86,063,000

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

0

Gross Profit (TTM)

0

EPS (TTM)

-1.57

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

N/A

ROE (TTM) (>15% strong)

-0.89%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

N/A

Momentum

Bearish momentum

Value

0.0107

Previous

0.0175

Trend

Falling

Signal Cross

No cross

As of

Sep. 12, 2025